1Surur AS,Teni FS, Girmay G,et al. Assessment of the structural and process aspects of pharmaceutical care at a university hospital in Ethiopia [J]. J Pharm Bioallied Sci, 2015,7(2) :97-102.
2Dabiri Y, Fahimi F, Jamaati H, et al. The comparison of extemporaneous preparations of omeprazole,pantoprazole oral suspension and intravenous pantoprazole on the gas- trie pH of critically ill-patients [J]. Indian J Crit Care Med, 2015,19(1) :21-26.
3Baysal B,Entrk H, Masri O,et al. Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspep- tic patients [J]. Turk J Gastroenterol, 2015,26(1) : 6-14.
4Yao DK,Chen H, Wang L, et al. Comparison of intra- venous plus oral pantoprazole therapy and oral pantopra- zole alone for preventing gastrointestinal bleeding in acute coronary syndrome patients with high bleeding risk [J]. Heart Lung Circ, 2015,14(15) : 122-125.
5Ramos-Martfn V,Paulus S, Siner S, et al. Population pharmacokinetics of teicoplanin in children [J]. Antimi- crob Agents Chemother, 2014,58( 11 ) : 6920-6927.
6Sato Y,Tokimatsu I, Suzuki Y,et al. Significance of high trough concentration of teicoplanin in the treatment of me- thicillin-resistant staphylococcus aureus infection [J]. Che- motherapy, 2015,60(4) : 274-278.
7Kim SW. Is therapeutic drug monitoring of teicoplanin useful? [J]. Infect Chemother, 2014,46(1) : 64-65.
8Chawla M,Malve H,Shah H,et al. Safety of intravenous insulin aspart compared to regular human insulin in pa- tients undergoing ICU monitoring post cardiac surgery:an Indian experience [J]. J Diabetes Metab Disord,2015,3 14) : 20-29.
9Yang W,Zhuang X,Li Y,et al. Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the Alchieve observational study [J]. Health Qual Life Outcomes , 2014, 26(12) : 137-145.
10Passanisi S, Timpanaro T, Lo Presti D, et al. Treatment of transient neonatal diabetes mellitus:insulin pump or in- sulin glargine? Our experience [J]. Diabetes Technol Ther,2014,16(12) :880-884.
